Showing results (111-120 of 231) with videos related to

Sort By:
Pageof 24
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|November 19, 2015
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerationsAnna Sarnelli, Francesco Guerriero, Francesca Botta, et al.
Cancer Medicine|July 1, 2014
Intensity-modulated pelvic radiation therapy and simultaneous integrated boost to the prostate area in patients with high-risk prostate cancer: a preliminary report of disease controlBiancamaria Saracino, Maria Grazia Petrongari, Simona Marzi, et al.
Oncology and Therapy|June 15, 2026
Evaluation of Drug-Drug Interactions Using Drug-PIN® in Patients Receiving Avelumab Maintenance for Advanced Urothelial Carcinoma: Evidence from the MALVA Study (Meet-URO 25)Giandomenico Roviello, Mattia Alberto Di Civita, Daniele Santini, et al.
Frontiers in Oncology|June 18, 2021
Personalized Treatment Planning Automation in Prostate Cancer Radiation Oncology: A Comprehensive Dosimetric StudySavino Cilla, Carmela Romano, Vittoria E Morabito, et al.
Plos One|August 15, 2017
Quantitative accuracy of 177Lu SPECT imaging for molecular radiotherapyEmilio Mezzenga, Vincenzo D'Errico, Marco D'Arienzo, et al.
Zeitschrift Fur Medizinische Physik|May 21, 2025
Advancing risk management in nuclear medicine diagnostic and therapy through incident-driven risk management toolsLidia Strigari, David Menichelli, Elisa Lodi Rizzini, et al.
Clinical & Experimental Metastasis|August 18, 2022
Stereotactic radiotherapy of nodal oligometastases from prostate cancer: a prisma-compliant systematic reviewAlice Zamagni, Mattia Bonetti, Milly Buwenge, et al.
Medical Physics|December 17, 2008
Color Doppler quantitative measures to predict outcome of biopsies in prostate cancerLidia Strigari, Annelisa Marsella, Stefano Canitano, et al.
Ebiomedicine|November 9, 2020
IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137<sup>+</sup>T-cellsAlessio Ugolini, Ilaria Grazia Zizzari, Fulvia Ceccarelli, et al.
Clinical & Experimental Metastasis|January 16, 2021
Systematic review of stereotactic body radiotherapy for nodal metastasesFrancesco Deodato, Gabriella Macchia, Milly Buwenge, et al.
Pageof 24